Phase II Plovamer Acetate Doses Compared to Copaxone in MS Patients

• Research type

  Research Study

• Full title

  A Phase II, Randomized, Multi-center, Parallel group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis.

• IRAS ID

  137276

• Contact name

  Basil Sharrack

• Contact email

  Basil.Sharrack@sth.nhs.uk

• Sponsor organisation

  Merck KGaA

• Eudract number

  2013-002283-25

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  14/EM/0023

• Date of REC Opinion

  18 Mar 2014

• REC opinion

  Further Information Favourable Opinion